Crenezumab
BN40031
Phase 3 small_molecule terminated
Quick answer
Crenezumab for Alzheimer's Disease is a Phase 3 program (small_molecule) at Hoffmann-La Roche with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Hoffmann-La Roche
- Indication
- Alzheimer's Disease
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- terminated